SARS-CoV-2, first emerged in the Hubei province of China in December 2019. The efficient transmission of the virus from person-to-person has contributed to the global spread of infection, better known as the COVID-19 pandemic. Patients with the highly infectious disease display flu-like symptoms such as cold and fever. The COVID-19 pandemic, caused by SARS-CoV-2, has become a public health emergency with over 200 countries affected. Genome sequence analysis has discovered that the virus is similar to that of SARS-CoV and MERS-CoV. Despite this, however, attempts to control SARS-CoV-2 with antiviral agents used to treat prior SARS-CoV and MERS-CoV infections have been found to be ineffective. As the rate of infection and deaths from COVID-19 increases, the pressure to find a vaccine solution builds. Efforts to develop antiviral agents against SARS-CoV-2 continue and the potential of multi-epitope vaccines will be further explored in this review. Multiple epitope targets of the spike (S) protein of SARS-CoV-2 are analyzed for their immunogenicity, stability, safety, and potential as vaccine candidates. The vaccine constructs discussed give promise of becoming vaccine candidates but require further in vitro and in vivo experimentation.